Regio Biosciences Enters into License Agreement with AstraZeneca for Phase 2a Asset in Peripheral Artery Disease (PAD) https://www.businesswire.com/news/home/20220203005202/en/Regio-Biosciences-Enters-into-License-Agreement-with-AstraZeneca-for-Phase-2a-Asset-in-Peripheral-Artery-Disease-PAD
Blocking endothelial lipase with monoclonal antibody MEDI5884 durably increases high density lipoprotein in nonhuman primates and in a phase 1 trial http://regiobiosciences.com/wp-content/uploads/2022/02/scitranslmed.abb0602.pdf
Endothelial Lipase (EL) which Demonstrate HDL-C Increase In Vivo http://regiobiosciences.com/wp-content/uploads/2022/02/Endothelial-Lipase-Inhibitor-BMS-2020.pdf
Optimal assessment of baseline treadmill walking performance in claudication clinical trials http://regiobiosciences.com/wp-content/uploads/2022/02/graded-treadmill-Vasc-Med-2007-Hiatt.pdf
